Zimmer Biomet (ZBH) Scheduled to Post Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) will issue its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of $1.98 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Zimmer Biomet Trading Down 3.0 %

Shares of ZBH opened at $107.04 on Tuesday. The business has a 50-day moving average of $109.75 and a 200 day moving average of $119.09. Zimmer Biomet has a fifty-two week low of $102.00 and a fifty-two week high of $133.90. The firm has a market cap of $22.02 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.01. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date was Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZBH. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, May 30th. Citigroup cut their price objective on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research report on Tuesday, May 21st. Piper Sandler downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $140.00 to $115.00 in a research report on Monday, July 1st. Finally, Truist Financial lowered their price objective on Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating for the company in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $129.81.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.